BioModels

The paper describes a model of resistance of cancer to chemotherapy. Created by COPASI 4.25 (Build 207) This model is described in the article: Modelling chemotherapy resistance in palliation and failed cure Helen C. Monro, Eamonn A. Gaffney J Theor Biol. 2009, 257 (2), pp.292 Abstract: The goal of palliative cancer chemotherapy treatment is to prolong survival and improve quality of life when tumour eradication is not feasible. Chemotherapy protocol design is considered in this context using a simple, robust, model of advanced tumour growth with Gompertzian dynamics, taking into account the effects of drug resistance. It is predicted that reduced chemotherapy protocols can readily lead to improved survival times due to the effects of competition between resistant and sensitive tumour cells. Very early palliation is also predicted to quickly yield near total tumour resistance and thus decrease survival duration. Finally, our simulations indicate that failed curative attempts using dose densification, a common protocol escalation strategy, can reduce survival times. To cite BioModels Database, please use: BioModels Database: An enhanced, curated and annotated resource for published quantitative kinetic models . To the extent possible under law, all copyright and related or neighbouring rights to this encoded model have been dedicated to the public domain worldwide. Please refer to CC0 Public Domain Dedication for more information.

• Modelling chemotherapy resistance in palliation and failed cure.
• Monro HC, Gaffney EA
• Journal of theoretical biology , 3/ 2009 , Volume 257 , Issue 2 , pages: 292-302 , PubMed ID: 19135065
Affiliation: University of Birmingham, Edgbaston, UK. monro@mat.bham.ac.uk
Abstract: The goal of palliative cancer chemotherapy treatment is to prolong survival and improve quality of life when tumour eradication is not feasible. Chemotherapy protocol design is considered in this context using a simple, robust, model of advanced tumour growth with Gompertzian dynamics, taking into account the effects of drug resistance. It is predicted that reduced chemotherapy protocols can readily lead to improved survival times due to the effects of competition between resistant and sensitive tumour cells. Very early palliation is also predicted to quickly yield near total tumour resistance and thus decrease survival duration. Finally, our simulations indicate that failed curative attempts using dose densification, a common protocol escalation strategy, can reduce survival times.